Genomic surveillance reveals a dengue 2 virus epidemic lineage with a marked decrease in sensitivity to Mosnodenvir

Hawa Sophia Bouzidi, Selin Sen, Géraldine Piorkowski, Laura Pezzi, Nazli Ayhan, Albin Fontaine, Thomas Canivez, Manon Geulen, Rayane Amaral, Gilda Grard, Guillaume André Durand, Xavier Lamballerie, Franck Touret () and Raphaëlle Klitting ()
Additional contact information
Hawa Sophia Bouzidi: IRBA)
Selin Sen: IRBA)
Géraldine Piorkowski: IRBA)
Laura Pezzi: IRBA)
Nazli Ayhan: IRBA)
Albin Fontaine: IRBA)
Thomas Canivez: IRBA)
Manon Geulen: IRBA)
Rayane Amaral: IRBA)
Gilda Grard: IRBA)
Guillaume André Durand: IRBA)
Xavier Lamballerie: IRBA)
Franck Touret: IRBA)
Raphaëlle Klitting: IRBA)

Nature Communications, 2024, vol. 15, issue 1, 1-11

Abstract: Abstract Dengue fever is the most important arbovirosis for public health, with more than 5 million cases worldwide in 2023. Mosnodenvir is the first anti-dengue compound with very high preclinical pan-serotype activity, currently undergoing phase 2 clinical evaluation. Here, by analyzing dengue virus (DENV) genomes from the 2023-2024 epidemic in the French Caribbean Islands, we show that they all exhibit mutation NS4B:V91A, previously associated with a marked decrease in sensitivity to mosnodenvir in vitro. Using antiviral activity tests on four clinical and reverse-genetic strains, we confirm a marked decrease in mosnodenvir sensitivity for DENV-2 ( > 1000 fold). Finally, combining phylogenetic analysis and experimental testing for resistance, we find that virus lineages with low sensitivity to mosnodenvir due to the V91A mutation likely emerged multiple times over the last 30 years in DENV-2 and DENV-3. These results call for increased genomic surveillance, in particular to track lineages with resistance mutations. These efforts should allow to better assess the activity profile of DENV treatments in development against circulating strains.

Date: 2024
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-024-52819-z Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-52819-z

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-024-52819-z

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().